Tizanidine

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released June 30, 1999; last updated July 23, 2017; expires July 23, 2020

Historical note and terminology

Tizanidine is a centrally acting alpha2-adrenergic agonist that was approved as an antispastic drug by the United States Food and Drug Administration in 1996.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.